Viking Therapeutics, Inc.

welcome to the viking therapeutics fourth quarter and full year 2024 financial results conference call at this time all participants are in a listen only mode following management's prepared remarks we will hold a question and answer session to ask a question you may press The star key followed by the number one on your touchtone phone. If anyone has difficulty hearing the conference, please press star and then zero for operator assistance. As a reminder, this conference call is being recorded today, February 5th, 2025. I would now like to turn the conference over to Vikings Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.

Hello, and thank you all for participating in today's call. Joining me today is Brian Leon, Vikings President and CEO, and Greg Zanti, Vikings CFO. Before we begin, I'd like to caution that comments made during this conference call today, February 5th, 2025, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Vikings' expectations regarding its development activities, timelines, and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. I'll now turn the call over to Brian Land for his initial comments.

Thanks, Stephanie, and good afternoon to everyone listening in by phone or on the webcast. Today, we'll review our financial results for the three months and full year ended December 31st, 2024, and provide an update on recent progress with our development programs and operations. 2024 was an exceptionally busy year for Viking. During the year, the company reported successful results from four different studies across our pipelines. These include the announcement of positive data from our VK2735 subcutaneous program for obesity, the results of our VK2735 oral tablet program for obesity, the histology results from our VK2809 program for the treatment of MASH and fibrosis, and the initial proof of concept data from our VK0214 program for XALD. With respect to VK2735, our lead program for obesity, In the first quarter of 2024, we announced positive results from the Phase II Venture Trial evaluating subcutaneous administration in obese subjects. This trial demonstrated impressive reductions in body weight after 13 weeks of treatment. Later in the first quarter, we announced the initial results from a 28-day Phase I trial evaluating an oral tablet formulation of DK2735, which demonstrated excellent tolerability and encouraging reductions in body weight. In the second quarter of 2024, we announced histology results from the Phase IIb voyage trial, evaluating our novel thyroid hormone receptor beta agonist, VK2809, for the treatment of MASH and fibrosis. This study successfully achieved its primary, secondary, and exploratory endpoints, showing reductions in liver fat at 12 weeks and improvements in MASH resolution rate and fibrosis after 52 weeks. And finally, in the fourth quarter of 2024, the company announced positive results from a 28-day Phase Ib clinical trial of our second novel thyroid hormone receptor beta agonist, VK0214, in patients with X-linked adrenal leukodystrophy, or XALD. Results from this study showed VK0214 to be safe and well-tolerated, and treated patients demonstrated significant reductions in plasma levels of very long-chain fatty acids compared with placebos. During the year, the company also announced the addition of a new program to its pipeline, focused on a series of internally developed agonists of the amylin receptor. In animal models, these compounds demonstrated improvements in body weight and metabolic profile. On the corporate side, during the first quarter of 2024, Viking closed a successful public offering of common stock, raising more than $630 million in gross proceeds, providing the resources to aggressively move forward with our pipeline programs. I'll have additional comments on our operations and development activities after we review our financial results for the fourth quarter and year-ending December 31st. For that, I'll turn the call over to Greg Zante, Vikings Chief Financial Officer.